Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology. In an exclusive interview, Chief Medical Officer Michael Cooreman joins Stephen Harrison and Roger Green to talk in depth about the company and key elements of its clinical development strategy for its pan-PPAR, lanifibranor.
